Brindle & Bay Financial Advisors LLC Purchases Shares of 6,042 Gilead Sciences, Inc. $GILD

Brindle & Bay Financial Advisors LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,042 shares of the biopharmaceutical company’s stock, valued at approximately $742,000.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Gilead Sciences by 12.0% in the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after purchasing an additional 1,618,453 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Gilead Sciences by 4.2% in the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock valued at $1,133,376,000 after purchasing an additional 414,454 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Gilead Sciences by 5.9% in the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock valued at $793,506,000 after purchasing an additional 400,002 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in shares of Gilead Sciences by 16.5% in the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after purchasing an additional 726,101 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $130.40 on Friday. The company has a market cap of $161.86 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.76 and a beta of 0.39. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29. The company’s fifty day simple moving average is $142.44 and its 200 day simple moving average is $132.13. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 8.63 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares in the company, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the transaction, the chief executive officer directly owned 613,912 shares of the company’s stock, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 178,640 shares of company stock worth $26,691,550. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Wolfe Research lifted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Mizuho lifted their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Finally, Daiwa Securities Group lifted their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $157.35.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.